Summary
IMvigor130 was a multicentre, phase 3 randomised controlled trial evaluating atezolizumab monotherapy and combination atezolizumab-chemotherapy against placebo in metastatic urothelial cancer. Published in The Lancet in 2020, the trial enrolled patients across multiple international centres and assessed immunotherapy efficacy as an alternative or adjunct to standard chemotherapy in this patient population.
UK applicability
Findings from this international trial would be relevant to UK oncology practice and NHS treatment guidelines for metastatic urothelial cancer. However, applicability depends on cost-effectiveness assessment and alignment with NICE technology appraisal criteria within the UK healthcare system.
Key measures
Overall survival, progression-free survival, response rates, adverse events
Outcomes reported
The study compared efficacy and safety of atezolizumab (an immune checkpoint inhibitor) with or without chemotherapy versus placebo in patients with metastatic urothelial cancer. Primary endpoints appear to be overall survival and progression-free survival.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.